Artwork

Content provided by Nessan Bermingham PhD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nessan Bermingham PhD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Episode 20: A Between the Biotech Waves conversation with Tom Barnes, CEO of ORNA Therapeutics

53:50
 
Share
 

Manage episode 345370118 series 3360242
Content provided by Nessan Bermingham PhD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nessan Bermingham PhD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millennium. Tom has deep biological pathway domain expertise and has worked across a broad range of therapeutic modalities, from genome editing, to RNA therapeutics, small molecules and proteins. Tom is a true scientist and drug hunter.

  continue reading

34 episodes

Artwork
iconShare
 
Manage episode 345370118 series 3360242
Content provided by Nessan Bermingham PhD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nessan Bermingham PhD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Today we are talking to Tom Barnes. Tom is CEO of Orna Therapeutics, a circular RNA focused biotech developing in situ CAR therapeutics. Orna recently announced a series B with a multi billion $ mega-deal with Merck. Prior to Orna Tom and I worked together at Intellia and also Ascelagen. Tom has also had leading positions at Eleven Bio and Millennium. Tom has deep biological pathway domain expertise and has worked across a broad range of therapeutic modalities, from genome editing, to RNA therapeutics, small molecules and proteins. Tom is a true scientist and drug hunter.

  continue reading

34 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide